MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from common
stock issued under...
$79,460K
Proceeds from issuance of
common stock under...
$21,194K
Proceeds from exercise of
warrants, net
$1,430K
Proceeds from exercise of
stock options
$1,270K
Proceeds from shares
issued under employee...
$110K
Net cash provided by
financing activities
$102,617K
Canceled cashflow
$847K
Net increase in cash
and cash...
$49,623K
Canceled cashflow
$52,994K
Payments for taxes on
share-based compensation
$810K
Repayment of debt
principal including lease...
$26K
Payments for royalty
obligations
$11K
Accounts payable
$19,523K
Amortization of debt issuance
costs and discounts
$10,995K
Share-based compensation
$7,624K
Accrued expenses and
other liabilities
$3,032K
Prepaid expenses and
other assets
-$698K
Depreciation and
amortization
$548K
Other, net
-$1K
Net cash used for
operating activities
-$52,432K
Net cash used for
investing activities
-$562K
Canceled cashflow
$42,421K
Net loss
-$83,784K
Capital expenditures
$562K
Trade receivables and
other receivables,...
$10,372K
Deferred revenue
-$571K
Inventories
$126K
Back
Back
Cash Flow
source: myfinsight.com
Aquestive Therapeutics, Inc. (AQST)
Aquestive Therapeutics, Inc. (AQST)